AAPL339.84-3.11 (-0.91%) ▼|ABBV290.72+8.04 (+2.85%) ▲|ABT102.61-1.46 (-1.40%) ▼|ACN238.96+2.03 (+0.86%) ▲|ADBE255.26+8.17 (+3.30%) ▲|AMAT406.46-6.65 (-1.61%) ▼|AMD542.18+4.13 (+0.77%) ▲|AMGN434.83+9.89 (+2.33%) ▲|AMT184.65+1.62 (+0.88%) ▲|AMZN263.10+0.65 (+0.25%) ▲|AVGO335.28+0.69 (+0.21%) ▲|AXP319.86+3.45 (+1.09%) ▲|BA191.31-0.12 (-0.06%) ▼|BAC50.80+0.41 (+0.81%) ▲|BKNG164.47+1.87 (+1.15%) ▲|BLK1,129.24+4.64 (+0.41%) ▲|BMY61.60+2.77 (+4.71%) ▲|BNY144.36+1.92 (+1.35%) ▲|BRK-B537.93+5.70 (+1.07%) ▲|C122.39+0.70 (+0.58%) ▲|CAT726.45+0.66 (+0.09%) ▲|CL94.02+1.16 (+1.24%) ▲|CMCSA22.21+0.31 (+1.39%) ▲|COF201.93+2.10 (+1.05%) ▲|COP145.84+0.60 (+0.41%) ▲|COST995.38-0.15 (-0.02%) ▼|CRM242.07-0.39 (-0.16%) ▼|CSCO106.63+0.13 (+0.12%) ▲|CVS94.11+1.43 (+1.54%) ▲|CVX224.76+0.39 (+0.17%) ▲|DE636.27+9.27 (+1.48%) ▲|DHR225.45+1.02 (+0.45%) ▲|DIS111.60+2.01 (+1.83%) ▲|DUK121.25+1.98 (+1.66%) ▲|EMR159.79-0.76 (-0.47%) ▼|FDX300.57+6.79 (+2.31%) ▲|GD344.41+2.98 (+0.87%) ▲|GE299.48-11.80 (-3.79%) ▼|GEV896.82-11.62 (-1.28%) ▼|GILD156.32+3.25 (+2.12%) ▲|GM75.90-6.86 (-8.28%) ▼|GOOG336.78-3.38 (-0.99%) ▼|GOOGL340.69-3.49 (-1.01%) ▼|GS885.74+9.96 (+1.14%) ▲|HD315.78+5.90 (+1.90%) ▲|HON212.18+2.20 (+1.05%) ▲|IBM240.33+3.94 (+1.67%) ▲|INTC92.54+0.51 (+0.55%) ▲|INTU336.52+10.90 (+3.35%) ▲|ISRG438.78+5.60 (+1.29%) ▲|JNJ259.72+5.93 (+2.34%) ▲|JPM335.76+2.23 (+0.67%) ▲|KO92.75-0.68 (-0.72%) ▼|LIN499.70-3.75 (-0.74%) ▼|LLY1,292.02+51.68 (+4.17%) ▲|LMT549.29+1.06 (+0.19%) ▲|LOW199.33+3.41 (+1.74%) ▲|LRCX265.14-7.06 (-2.59%) ▼|MA622.00+5.60 (+0.91%) ▲|MCD245.62+2.95 (+1.21%) ▲|MDLZ63.87+0.53 (+0.83%) ▲|MDT94.57+1.80 (+1.94%) ▲|META690.14-15.30 (-2.17%) ▼|MMM171.17+9.16 (+5.65%) ▲|MO74.43+0.34 (+0.46%) ▲|MRK148.25+4.62 (+3.22%) ▲|MS180.42+1.95 (+1.09%) ▲|MSFT532.48-1.04 (-0.19%) ▼|MU909.62+4.72 (+0.52%) ▲|NEE78.83+0.66 (+0.84%) ▲|NFLX69.29-0.56 (-0.80%) ▼|NKE37.95+0.74 (+1.98%) ▲|NOW149.61+4.25 (+2.92%) ▲|NVDA217.09+0.00 (+0.00%) ▲|ORCL131.78+2.19 (+1.69%) ▲|PEP134.26+0.69 (+0.52%) ▲|PFE30.24+0.80 (+2.70%) ▲|PG158.22+0.53 (+0.33%) ▲|PLTR195.76+1.61 (+0.83%) ▲|PM200.05-1.00 (-0.50%) ▼|QCOM176.25+2.72 (+1.57%) ▲|RTX191.57-0.55 (-0.28%) ▼|SBUX99.44+1.57 (+1.60%) ▲|SCHW90.69+1.11 (+1.24%) ▲|SO90.80+1.53 (+1.71%) ▲|SPG205.95+3.46 (+1.71%) ▲|T23.55+0.35 (+1.49%) ▲|TMO690.26+10.88 (+1.60%) ▲|TMUS157.96+1.87 (+1.20%) ▲|TSLA374.66+6.60 (+1.79%) ▲|TXN279.33+3.18 (+1.15%) ▲|UBER69.00-0.96 (-1.37%) ▼|UNH420.66+13.78 (+3.39%) ▲|UNP288.10+1.09 (+0.38%) ▲|UPS99.00+1.54 (+1.58%) ▲|USB58.91+1.06 (+1.83%) ▲|V407.29+4.37 (+1.08%) ▲|VZ44.56+0.41 (+0.92%) ▲|WFC81.64-0.17 (-0.20%) ▼|WMT118.35-0.35 (-0.29%) ▼|XOM177.16-1.12 (-0.63%) ▼|AAPL339.84-3.11 (-0.91%) ▼|ABBV290.72+8.04 (+2.85%) ▲|ABT102.61-1.46 (-1.40%) ▼|ACN238.96+2.03 (+0.86%) ▲|ADBE255.26+8.17 (+3.30%) ▲|AMAT406.46-6.65 (-1.61%) ▼|AMD542.18+4.13 (+0.77%) ▲|AMGN434.83+9.89 (+2.33%) ▲|AMT184.65+1.62 (+0.88%) ▲|AMZN263.10+0.65 (+0.25%) ▲|AVGO335.28+0.69 (+0.21%) ▲|AXP319.86+3.45 (+1.09%) ▲|BA191.31-0.12 (-0.06%) ▼|BAC50.80+0.41 (+0.81%) ▲|BKNG164.47+1.87 (+1.15%) ▲|BLK1,129.24+4.64 (+0.41%) ▲|BMY61.60+2.77 (+4.71%) ▲|BNY144.36+1.92 (+1.35%) ▲|BRK-B537.93+5.70 (+1.07%) ▲|C122.39+0.70 (+0.58%) ▲|CAT726.45+0.66 (+0.09%) ▲|CL94.02+1.16 (+1.24%) ▲|CMCSA22.21+0.31 (+1.39%) ▲|COF201.93+2.10 (+1.05%) ▲|COP145.84+0.60 (+0.41%) ▲|COST995.38-0.15 (-0.02%) ▼|CRM242.07-0.39 (-0.16%) ▼|CSCO106.63+0.13 (+0.12%) ▲|CVS94.11+1.43 (+1.54%) ▲|CVX224.76+0.39 (+0.17%) ▲|DE636.27+9.27 (+1.48%) ▲|DHR225.45+1.02 (+0.45%) ▲|DIS111.60+2.01 (+1.83%) ▲|DUK121.25+1.98 (+1.66%) ▲|EMR159.79-0.76 (-0.47%) ▼|FDX300.57+6.79 (+2.31%) ▲|GD344.41+2.98 (+0.87%) ▲|GE299.48-11.80 (-3.79%) ▼|GEV896.82-11.62 (-1.28%) ▼|GILD156.32+3.25 (+2.12%) ▲|GM75.90-6.86 (-8.28%) ▼|GOOG336.78-3.38 (-0.99%) ▼|GOOGL340.69-3.49 (-1.01%) ▼|GS885.74+9.96 (+1.14%) ▲|HD315.78+5.90 (+1.90%) ▲|HON212.18+2.20 (+1.05%) ▲|IBM240.33+3.94 (+1.67%) ▲|INTC92.54+0.51 (+0.55%) ▲|INTU336.52+10.90 (+3.35%) ▲|ISRG438.78+5.60 (+1.29%) ▲|JNJ259.72+5.93 (+2.34%) ▲|JPM335.76+2.23 (+0.67%) ▲|KO92.75-0.68 (-0.72%) ▼|LIN499.70-3.75 (-0.74%) ▼|LLY1,292.02+51.68 (+4.17%) ▲|LMT549.29+1.06 (+0.19%) ▲|LOW199.33+3.41 (+1.74%) ▲|LRCX265.14-7.06 (-2.59%) ▼|MA622.00+5.60 (+0.91%) ▲|MCD245.62+2.95 (+1.21%) ▲|MDLZ63.87+0.53 (+0.83%) ▲|MDT94.57+1.80 (+1.94%) ▲|META690.14-15.30 (-2.17%) ▼|MMM171.17+9.16 (+5.65%) ▲|MO74.43+0.34 (+0.46%) ▲|MRK148.25+4.62 (+3.22%) ▲|MS180.42+1.95 (+1.09%) ▲|MSFT532.48-1.04 (-0.19%) ▼|MU909.62+4.72 (+0.52%) ▲|NEE78.83+0.66 (+0.84%) ▲|NFLX69.29-0.56 (-0.80%) ▼|NKE37.95+0.74 (+1.98%) ▲|NOW149.61+4.25 (+2.92%) ▲|NVDA217.09+0.00 (+0.00%) ▲|ORCL131.78+2.19 (+1.69%) ▲|PEP134.26+0.69 (+0.52%) ▲|PFE30.24+0.80 (+2.70%) ▲|PG158.22+0.53 (+0.33%) ▲|PLTR195.76+1.61 (+0.83%) ▲|PM200.05-1.00 (-0.50%) ▼|QCOM176.25+2.72 (+1.57%) ▲|RTX191.57-0.55 (-0.28%) ▼|SBUX99.44+1.57 (+1.60%) ▲|SCHW90.69+1.11 (+1.24%) ▲|SO90.80+1.53 (+1.71%) ▲|SPG205.95+3.46 (+1.71%) ▲|T23.55+0.35 (+1.49%) ▲|TMO690.26+10.88 (+1.60%) ▲|TMUS157.96+1.87 (+1.20%) ▲|TSLA374.66+6.60 (+1.79%) ▲|TXN279.33+3.18 (+1.15%) ▲|UBER69.00-0.96 (-1.37%) ▼|UNH420.66+13.78 (+3.39%) ▲|UNP288.10+1.09 (+0.38%) ▲|UPS99.00+1.54 (+1.58%) ▲|USB58.91+1.06 (+1.83%) ▲|V407.29+4.37 (+1.08%) ▲|VZ44.56+0.41 (+0.92%) ▲|WFC81.64-0.17 (-0.20%) ▼|WMT118.35-0.35 (-0.29%) ▼|XOM177.16-1.12 (-0.63%) ▼|
17.9 C
New York
Tuesday, October 20, 2026

Tag: preclinical

newsFORsourcecompanycontentinformation1releasesmarket

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 5, 2025 to report its second quarter 2025 financial results and provide a corporate update.

Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

Liminatus Pharma reviews digital asset treasury strategies to enhance capital efficiency.

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention 

New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced completion of its Nasdaq IPO ceremony, and that it participated at the world's largest biotechnology exhibition BIO 2025 International Convention, where it engaged with other global pharmaceutical companies.

Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology

New research paper highlights the unique structure and function of Nanoscope's synthetic opsin, supporting its potential in vision restoration DALLAS, July 22, 2025 /PRNewswire/...

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including...

DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – –...

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

ORION CORPORATION
PRESS RELEASE
21 JULY 2025 at 10:30 EEST          

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPreclinical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers